Mpox across countries from Central and Eastern Europe - 2022 outbreak
Copyright © 2024. Published by Elsevier Ltd..
BACKGROUND: The aim of the study was to assess socio-demographical characteristics, clinical presentation, and outcomes in patients diagnosed with mpox.
METHODS: A survey on patients diagnosed with mpox was performed in 14 countries from Central and Eastern Europe. Data was compared according to HIV status and country of origin (EU vs. non-EU). Mpox diagnosis was confirmed by RT-PCR from oropharyngeal swabs, skin lesions, and other body fluids.
RESULTS: Out of 154 patients confirmed with mpox in 2022, 99.3% were males, with a median age (years) of 35 (IQR 30-39), 90.2% MSM and 48.7% PLWH. Compared to HIV-negative subjects, PLWH had more frequent high-risk behaviours:chemsex (p = 0.015), group sex (p = 0.027), and a history of sexually transmitted infections (STIs) (p = 0.004). Persons from EU were more often PLWH (p = 0.042), MSM (p < 0.0001), had multiple sexual partners (p = 0.025), practiced chemsex (p = 0.008) or group-sex (p = 0.005) and had more often history of STIs (p < 0.0001). The median CD4 cell count/mL at mpox diagnosis was 713 (IQR 486-996) and 73.5% had undetectable HIV VL. The commonest clinical features were fever (108 cases), lymphadenopathy (78), and vesiculo-pustular rash: penile (76), perianal (48), limbs (67). Fifty-one (31%) persons were hospitalized due to complications or epidemiological reasons. Three patients received tecovirimat or cidofovir. The outcome was favorable for all patients, including 4 with severe forms.
CONCLUSIONS: Mpox was diagnosed predominantly in young MSM, with high-risk behaviors and history of STIs. Effective contact tracing and vaccination are important strategic pillars to control mpox outbreaks.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:59 |
|---|---|
| Enthalten in: |
Travel medicine and infectious disease - 59(2024) vom: 02. Apr., Seite 102719 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ianache, Irina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 06.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.tmaid.2024.102719 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370642058 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370642058 | ||
| 003 | DE-627 | ||
| 005 | 20240407232440.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240405s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.tmaid.2024.102719 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1368.xml |
| 035 | |a (DE-627)NLM370642058 | ||
| 035 | |a (NLM)38574784 | ||
| 035 | |a (PII)S1477-8939(24)00033-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ianache, Irina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mpox across countries from Central and Eastern Europe - 2022 outbreak |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 06.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024. Published by Elsevier Ltd. | ||
| 520 | |a BACKGROUND: The aim of the study was to assess socio-demographical characteristics, clinical presentation, and outcomes in patients diagnosed with mpox | ||
| 520 | |a METHODS: A survey on patients diagnosed with mpox was performed in 14 countries from Central and Eastern Europe. Data was compared according to HIV status and country of origin (EU vs. non-EU). Mpox diagnosis was confirmed by RT-PCR from oropharyngeal swabs, skin lesions, and other body fluids | ||
| 520 | |a RESULTS: Out of 154 patients confirmed with mpox in 2022, 99.3% were males, with a median age (years) of 35 (IQR 30-39), 90.2% MSM and 48.7% PLWH. Compared to HIV-negative subjects, PLWH had more frequent high-risk behaviours:chemsex (p = 0.015), group sex (p = 0.027), and a history of sexually transmitted infections (STIs) (p = 0.004). Persons from EU were more often PLWH (p = 0.042), MSM (p < 0.0001), had multiple sexual partners (p = 0.025), practiced chemsex (p = 0.008) or group-sex (p = 0.005) and had more often history of STIs (p < 0.0001). The median CD4 cell count/mL at mpox diagnosis was 713 (IQR 486-996) and 73.5% had undetectable HIV VL. The commonest clinical features were fever (108 cases), lymphadenopathy (78), and vesiculo-pustular rash: penile (76), perianal (48), limbs (67). Fifty-one (31%) persons were hospitalized due to complications or epidemiological reasons. Three patients received tecovirimat or cidofovir. The outcome was favorable for all patients, including 4 with severe forms | ||
| 520 | |a CONCLUSIONS: Mpox was diagnosed predominantly in young MSM, with high-risk behaviors and history of STIs. Effective contact tracing and vaccination are important strategic pillars to control mpox outbreaks | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Central and Eastern Europe | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a mpox | |
| 700 | 1 | |a Skrzat-Klapaczynska, Agata |e verfasserin |4 aut | |
| 700 | 1 | |a Jilich, David |e verfasserin |4 aut | |
| 700 | 1 | |a Fleischhans, Lukas |e verfasserin |4 aut | |
| 700 | 1 | |a Gmizic, Ivana |e verfasserin |4 aut | |
| 700 | 1 | |a Ranin, Jovan |e verfasserin |4 aut | |
| 700 | 1 | |a Papadopoulos, Antonios |e verfasserin |4 aut | |
| 700 | 1 | |a Protopapas, Konstantinos |e verfasserin |4 aut | |
| 700 | 1 | |a Mulabdic, Velida |e verfasserin |4 aut | |
| 700 | 1 | |a Lakatos, Botond |e verfasserin |4 aut | |
| 700 | 1 | |a Nagy, Eva Livia |e verfasserin |4 aut | |
| 700 | 1 | |a Begovac, Josip |e verfasserin |4 aut | |
| 700 | 1 | |a Holban, Tiberiu |e verfasserin |4 aut | |
| 700 | 1 | |a Sevgi, Dilek Yildiz |e verfasserin |4 aut | |
| 700 | 1 | |a Cicic, Alma |e verfasserin |4 aut | |
| 700 | 1 | |a Yancheva, Nina |e verfasserin |4 aut | |
| 700 | 1 | |a Sojak, Lubomir |e verfasserin |4 aut | |
| 700 | 1 | |a Rukhadze, Nino |e verfasserin |4 aut | |
| 700 | 1 | |a Kowalska, Justyna |e verfasserin |4 aut | |
| 700 | 1 | |a Oprea, Cristiana |e verfasserin |4 aut | |
| 700 | 0 | |a ECEE Network Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Travel medicine and infectious disease |d 2003 |g 59(2024) vom: 02. Apr., Seite 102719 |w (DE-627)NLM16457655X |x 1873-0442 |7 nnns |
| 773 | 1 | 8 | |g volume:59 |g year:2024 |g day:02 |g month:04 |g pages:102719 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.tmaid.2024.102719 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 59 |j 2024 |b 02 |c 04 |h 102719 | ||